Introduction
Acute heart failure (AHF) is the most common hospital discharge diagnosis among Medicare beneficiaries and accounts for more than half of all heart failure related expenditures.
1 -3 This epidemic of AHF is driven primarily by congestion, leaving loop diuretics as the primary tool to treat AHF. 4 in the response to loop diuretics, termed diuretic resistance, is common and strongly associated with poorer survival. 9 -13 Despite the fact that loop diuretics represent the cornerstone of therapy for AHF, there are substantial gaps in our understanding of the mechanisms underlying diuretic resistance. Notably, the guiding principles upon which we approach diuretic resistance were derived from studies of either normal or hypertensive populations where the pathobiology of sodium handling is likely to be very different from that of AHF.
14 -16 Furthermore, the handful of small studies in patients with heart failure were largely conducted in stable heart failure patients in an era before widespread use of neurohormonal antagonists was the standard of care. 17 -19 One of the most proximal branch points in the mechanisms for diuretic resistance centres on defects in drug delivery vs. loss of target responsiveness to the drug (i.e. pharmacokinetic vs. pharmacodynamic limitations). For example, patients with severe chronic kidney disease (CKD) are known to have essentially a normal tubular response to loop diuretics, with the primary mechanism for diuretic resistance being impaired delivery of diuretic to the tubule (i.e. pharmacokinetic limitations). 20, 21 However, therapies with important pharmacokinetic advantages, such as continuous loop diuretic infusions, have yielded disappointing results in AHF and contemporary studies have not found renal dysfunction to be a predominant driver of diuretic resistance in AHF. 10, 22 As such, the purpose of the present study was to determine the relative importance of pharmacokinetic vs. pharmacodynamic factors on loop diuretic responsiveness in patients with AHF. Our hypothesis was that defects in drug delivery would explain only a minor proportion of diuretic resistance in a contemporary AHF population.
Methods

Patient population
Patients admitted with AHF to both the general cardiology and advanced heart failure services at Yale New Haven Hospital were eligible. Inclusion criteria were intentionally broad to enrol a generalizable population, and included a diagnosis of heart failure and treatment with intravenous loop diuretics. Enrolment could occur at any time during hospitalization. Known bladder dysfunction, incontinence, or inability to comply with timed urine collections were exclusion criteria. All patients received bumetanide, the dose of which was determined by the treating physician. By protocol, patients could not have received a dose of diuretics after midnight, which avoided an effect from residual diuretics as this was after approximately six times the half-life of bumetanide (1.5 h). All patients provided written informed consent and the study was approved by the Yale Institutional Review Board.
Urine collection
Patients were asked to completely empty their bladder before administration of the morning intravenous diuretic dose. Following administration, a timed 6-h urine collection with thorough supervision by study staff began. During the following 6 h the cumulative urine produced was collected and the collection was terminated with a forced void after 6 h. We chose a 6-h collection period as it has been described that natriuresis from a dose of intravenous bumetanide or furosemide is complete within this period. 23, 24 Assays Baseline serum and plasma laboratory values were obtained from the patients' routine clinical morning lab results. Urine electrolytes were measured via indirect ion sensitive electrodes on the Randox Daytona clinical chemistry analyser (Randox Laboratories, Ireland, UK).
sodium was below the detection limit, samples were diluted 1:1 with normal saline, reanalysed and the final result calculated after accounting for the dilution. Urine creatinine was determined using a modified Jaffe method. Bumetanide in urine was measured using the Agilent UHPLC-Q-TOF mass spectrometer on the Agilent Infinity 1290 UPLC system. 25 Chromatographic separation was achieved on the Zorbax Bonus RP 2.1 × 50 mm 1.8 μ column (Santa Clara CA, USA) at a flow rate of 0.6 mL/min. The mobile phase consisted of 0.1% formic acid and 80% acetonitrile in 0.1% formic acid. The retention time was 4 .08 min and the total run time was 10 min. Mass spectrometry was performed on Agilent Q-TOF system. The detection was performed in positive ion mode. A stock solution of bumetanide was prepared in 0.1% formic acid at a concentration of 10 μg/mL. The highest standard used was 2000 ng/mL, and this was further serially diluted to obtain 1000, 500, 250, 125, 62.5, and 31.5 ng/mL. All the standards were run in duplicate.
Calculations
The chronic kidney disease epidemiology collaboration (CKD-EPI) equation was used to calculate estimated glomerular filtration rate (eGFR). 26 Creatinine clearance was calculated using the 6-h urinary creatinine excretion divided by serum creatinine, multiplied by the urine volume per minute. Urea clearance was obtained similarly. We calculated net sodium excretion over 6 h by multiplying the concentration of sodium in the urine by the total urine volume during this period. Fractional excretion of sodium (FENa) was calculated using the equation: (urine sodium × plasma creatinine)/(plasma sodium × urine creatinine) × 100. Serum anion gap was calculated by adding serum chloride to serum carbon dioxide, minus serum sodium. A poor natriuretic response was defined as <50 mmol of sodium output over 6 h. 27 Unmeasured anion excretion was calculated as the urine anion gap (urine sodium + urine potassium -urine chloride) multiplied by the total urine volume.
Definitions
Urinary diuretic excretion
The 6-h cumulative bumetanide excretion was calculated as total 6-h urine volume multiplied by the bumetanide concentration. Relative renal bumetanide clearance was calculated by dividing the 6-h bumetanide excretion by the intravenous bumetanide dose administered.
Diuretic response
Four different definitions of diuretic response (DR) were calculated. Table 1 describes these four metrics and what information they capture. As it is well described in the literature that the dose-response relationship of a loop diuretic is log linear, the DR metrics presented are per doubling of the quantity of diuretic. 21 A detailed description of the rationale and validation of this formula can be found in the Supplementary material online, Methods S1. The intravenous doses were centred on a dose of 0.5 mg bumetanide and doses less than 1 mg were winsorized to 1 mg in order to avoid division by zero. A centring value of 0.5 mg was chosen as it has been reported that 40 mg of furosemide (equivalent to 1 mg of bumetanide, i.e. one doubling of a 0.5 mg dose) will result in maximal natriuresis in a normal subject and this is a common multiplier in clinical dosing diuretics. 28 This resulted in the following formula: natriuresis/[(Log2 administered bumetanide) + 1]. As diuretic excretion of bumetanide in the urine was roughly 50% in this cohort, urinary diuretic doses were centred on a dose of 0.25 mg bumetanide (i.e. a dose of 0.5 mg was considered to be one doubling) and doses less than 0.5 mg were winsorized to 0.5 mg. This resulted in the following formula: natriuresis/[(Log2 bumetanide excreted in urine) + 2].
Statistical analysis
Data with a normal distribution are presented as mean ± standard deviations. Categorical values are presented as frequencies and percentages and data with a skewed distribution are shown as median with interquartile ranges (IQR 
Results
A total of 50 patients completed the 6-h urine collection protocol and were included in the analysis. Baseline characteristics of the overall population are presented in Table 2 . Median intravenous bumetanide dose was 3.0 (IQR 2.0-4.0) mg, which, over 6 h resulted in a total sodium excretion of 54. 
Renal bumetanide clearance
Median excretion of bumetanide was 1.7 (IQR 0.7-2.5) mg over the 6-h study period which translated to a median of 52 (IQR 33-77)% of intravenously administered dose (10th and 90th percentiles were 20% and 87%, respectively). However, significant between-patient variability in the degree of renal excretion was present as the administered dose only explained 39% of variability in the quantity of bumetanide ultimately recovered in the urine ( Figure 1) . Consistent with the known mechanisms by which loop diuretics undergo renal clearance, the majority of parameters related to either renal function or organic ion handling were correlated with relative renal bumetanide clearance (Table 3) . Notably, urea clearance, a parameter influenced by both renal blood flow and renal filtration, was most strongly correlated with bumetanide clearance (r 2 = 0.56, P < 0.0001). The combination of serum anion gap, total 6-h unmeasured urine anion excretion, and urea clearance could explain 64% of the variance in renal bumetanide clearance (P < 0.0001).
Global diuretic response
Whole-kidney sodium DR was 21.3 mmol Na per doubling of administered diuretic dose (IQR 12.5-45.1), and whole-kidney FENa DR was 1.30% (increase in fractional sodium excretion) per doubling of administered diuretic dose (IQR 0.68-2.47). The dose of administered bumetanide was not correlated with either metric of whole-kidney DR ( Table 4) . Relative renal bumetanide clearance could explain 23% of the whole-kidney sodium DR (P < 0.001). However, there was no correlation between relative renal bumetanide clearance and whole-kidney FENa DR ( Table 4) . Whole-kidney sodium DR demonstrated a moderate strength positive correlation with all available metrics of renal function (Table 5) , with urea clearance having the strongest association. In eGFR, estimated glomerular filtration rate. Relative renal bumetanide clearance is the 6-h bumetanide excretion divided by the administered intravenous bumetanide dose; unmeasured anion excretion: is the urine anion gap (urine sodium + urine potassium -urine chloride) multiplied by the total urine volume; serum anion gap is determined by adding serum chloride to serum carbon dioxide, minus serum sodium. * Log transformed.
contrast, there was either no correlation or an inverse correlation between the whole-kidney FENa DR and metrics of renal function ( Table 5) . Both whole-kidney sodium DR and whole-kidney FENa DR were unrelated to the degree of congestion, as estimated by jugular venous pressure, oedema, and pulmonary crackles on the day of the study (P > 0.2 for all comparisons).
Multivariable predictors of global diuretic response
We next sought to construct a multivariable linear regression model to better understand the relative contributors to whole-kidney sodium DR as this metric represents the sum of . both pharmacokinetic and pharmacodynamic limitations to DR. Pharmacokinetic factors influencing drug delivery such as diuretic dose, relative renal bumetanide clearance, and urea clearance explained a total of 28% of the variance in whole-kidney sodium DR. Importantly, all of these factors were highly collinear and largely captured the same variance. For example, urea clearance explained 26% and relative renal bumetanide clearance 23% of the variance in whole-kidney sodium DR. However, the addition of relative renal bumetanide clearance to a model containing urea clearance only added 2% incrementally to the model. Resistance at the level of the renal tubule captured by tubular sodium DR, which is calculated using the diuretic that was actually delivered to the tubular site of action, explained an additional 71% of the variance in whole-kidney sodium DR (Figure 2) . Notably, we were unable to identify pharmacokinetic factors that could explain whole-kidney FENa DR; however tubular FENa DR explained 87% of the variance in whole-kidney FENa DR.
Renal dysfunction
To further examine the effect of renal function on diuretic excretion and response, we divided patients in two groups based on the presence or absence of significant renal dysfunction (eGFR <60 mL/min/1.73 m 2 ). Table 2 shows that patients with significant renal dysfunction received higher doses of bumetanide but did not have differences in total urine output, total sodium output, or the total quantity of bumetanide excreted into the urine (Figure 3) . However, the post-diuretic 6-h FENa was approximately twice as high in patients with renal dysfunction (Table 2) . Notably, 1 h 
Discussion
The primary findings of this study are: (i) the amount of administered loop diuretic that actually reaches the tubular site of action is highly variable between individual heart failure patients; (ii) the major source of this variability in renal diuretic excretion is driven by parameters related to kidney function; (iii) despite this variability, the primary driver for DR was resistance at the level of the renal tubule; and (iv) patients with renal dysfunction had a significantly better DR at the level of the renal tubule than patients without renal dysfunction, in part explaining the lack of importance of renal dysfunction on overall diuresis, natriuresis, and DR.
We found that delivery of bumetanide to the tubular site of action was highly variable between patients. Notably, the relative amount of drug excreted in the urine varied more than threefold between the 10th percentile and 90th percentile in the population and the quantity of diuretic administered to the patient only explained 39% of bumetanide that was ultimately recovered in the urine. Consistent with previous literature, the predominant factors responsible for this variability in delivery of bumetanide were all related to kidney function. We found that the majority of the variability in drug delivery could be explained by the anion gap [i.e. competition with organic anion transporter (OAT)], the amount of unmeasured urine anions cleared (i.e. a surrogate for OAT transport effectiveness), and urea clearance (i.e. a surrogate for renal blood flow, filtration, and urea absorption). The fact that a negligible amount of loop diuretic undergoes filtration, and the majority is secreted as a result of the high protein binding of these drugs, explains why urea clearance had a stronger association than did creatinine clearance or eGFR. However, despite our observation that there was substantial variability in the amount of diuretic delivered to the tubular site of action, we found that this was only a minor factor in determining net DR. The explanation for this paradox can in part be found by revisiting some of the known pharmacokinetic and pharmacodynamic principles of loop diuretics. In normal subjects administration of 40 mg of furosemide results in 3000-4000 mL of urine output. 20 However, in AHF populations the median fluid output per 40 mg of furosemide is profoundly decreased and reported to range from 150 to 500 mL per 40 mg of furosemide across populations. 10, 13 Multiple studies have described a sigmoidal and log-linear dose-response curve of loop diuretics, which appears to apply to populations ranging from healthy subjects to those with heart failure. 17, 18, 20, 21 As a result of this log-linear relationship, it takes large increases in the dose of loop diuretic . 22 the high dose intervention randomized patients to 2.5 times higher doses of loop diuretic, but this only resulted in a 37% increase in fluid loss (see Supplementary material online, Figure S1 ). Given that urine diuretic concentration (i.e. delivery to the renal tubular site of action) is linearly related to the serum concentration and thus the intravenous dose, this means that massive defects in drug secretion would be required to meaningfully alter DR. Given that DR in heart failure populations is 5-10-fold worse than that seen in normal volunteers, and large changes in drug delivery result in small changes in DR, it becomes clear how despite a large variability in the percentage of drug reaching the tubular site of action, very little of DR is actually driven by this parameter.
Diuretic response and renal function
Extrapolated from a large body of literature in patients with CKD, renal dysfunction is often assumed to be a/the predominant driver of DR in patients with AHF. It has been well described in the literature that renal dysfunction is associated with substantially worse urinary diuretic delivery, a finding we confirmed in the present study. 21 However, the intrinsic tubular response, as assessed by FENa, in patients with CKD is known to be the same as in normal subjects. Thus by overcoming the reduced diuretic secretion with higher administered doses, for any given tubular diuretic concentration, maximal FENa will be the same between patients with or without CKD (i.e. the tubular FENa DR should be the same between CKD and normal subjects). One caveat here is that despite a similar FENa DR, the absolute number of nephrons is lower with CKD. As the total sodium output is the product of GFR × FENa, the total sodium output would be expected to be substantially lower in patients with renal dysfunction, even if the FENa was the same. 27 As such, although we might have anticipated a minimal impact from reduced diuretic delivery associated with renal dysfunction, the reduced total nephron mass should result in significantly lower overall DR. Surprisingly, we did not observe any difference in natriuresis, diuresis, and overall DR in AHF patient with or without . renal dysfunction. The primary driver for this observation was that tubular FENa DR was actually much better in patients with significant renal dysfunction. Put another way, for any given amount of diuretic delivered to the tubular site of action, the FENa was twice as high in patients with renal dysfunction than in those without renal dysfunction, making up for the reduced total nephron mass. This appeared to be driven by an overall superior tubular response, rather than prolonged natriuretic response, as the FENa at 1 h and 2 h were also approximately twice as high in those with renal dysfunction than in those without renal dysfunction. A notable additional finding was that pre-diuretic FENa was also significantly higher in patients with renal dysfunction. Although beyond the scope of the present investigation, these observations suggest that intrinsic sodium avidity is somehow regulated in such a way that net sodium balance can be preserved across the spectrum of GFR, even in patients with heart failure. While the present study has informed the question of renal tubular resistance vs. diuretic delivery, the next level of understanding will require the probing of specific tubular locations for the resistance-data that was not available in the cohort in the present study.
Limitations
There are several limitations that warrant discussion. First, despite the intense supervision of biospecimen collection by study staff, the present study took place in the 'real world' of ill, hospitalized AHF patients. As such, the majority of patients did not have an indwelling bladder catheter and some patients were unable to void at baseline or at the conclusion of the study. This is a potential limitation as residual urine in the bladder may have influenced the precision of our assessment of natriuresis and bumetanide excretion because some urine may have remained in the bladder before initiation of, and at the conclusion of, the 6-h timed urine. While this limitation may lead to quantitative errors, we would not expect the findings to quantitatively change even with the use of bladder catheters. Enrolment could occur at any time during hospitalization and thus we are unable to comment specifically about the mechanism of diuretic resistance at specific phases in the treatment of decompensated heart failure. Bumetanide was chosen because of its consistent pharmacokinetics in patients with renal dysfunction; however, this may limit generalizability to patients treated with furosemide. Construction of formal patient level dose-response curves would have been informative, but unfortunately owing to the design of the study serial blood and . 
Conclusions
Defects at the level of the renal tubule are substantially more important than reduced diuretic delivery in determining diuretic resistance in patients with AHF. These findings explain why renal dysfunction plays a limited role in determining DR in AHF.
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